PL374121A1 - Sposoby i materiały do leczenia niedoboru testosteronu u ludzi - Google Patents

Sposoby i materiały do leczenia niedoboru testosteronu u ludzi

Info

Publication number
PL374121A1
PL374121A1 PL02374121A PL37412102A PL374121A1 PL 374121 A1 PL374121 A1 PL 374121A1 PL 02374121 A PL02374121 A PL 02374121A PL 37412102 A PL37412102 A PL 37412102A PL 374121 A1 PL374121 A1 PL 374121A1
Authority
PL
Poland
Prior art keywords
methods
men
treatment
materials
testosterone deficiency
Prior art date
Application number
PL02374121A
Other languages
English (en)
Other versions
PL211339B1 (pl
Inventor
Joseph S. Podolski
Original Assignee
Zonagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL374121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zonagen, Inc. filed Critical Zonagen, Inc.
Publication of PL374121A1 publication Critical patent/PL374121A1/pl
Publication of PL211339B1 publication Critical patent/PL211339B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
PL374121A 2001-07-09 2002-07-09 Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków PL211339B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09

Publications (2)

Publication Number Publication Date
PL374121A1 true PL374121A1 (pl) 2005-10-03
PL211339B1 PL211339B1 (pl) 2012-05-31

Family

ID=23175972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374121A PL211339B1 (pl) 2001-07-09 2002-07-09 Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków

Country Status (23)

Country Link
US (6) US7759360B2 (pl)
EP (1) EP1411916B1 (pl)
JP (2) JP4845165B2 (pl)
KR (1) KR100851648B1 (pl)
CN (2) CN1954807A (pl)
AT (1) ATE406153T1 (pl)
AU (1) AU2002318225B2 (pl)
BR (1) BR0211067A (pl)
CA (2) CA2777199A1 (pl)
CL (1) CL2004000026A1 (pl)
CO (1) CO5550428A2 (pl)
CY (1) CY1108563T1 (pl)
DE (1) DE60228583D1 (pl)
DK (1) DK1411916T3 (pl)
EC (1) ECSP044937A (pl)
ES (1) ES2312593T3 (pl)
MX (1) MXPA04000097A (pl)
NZ (2) NZ551013A (pl)
PL (1) PL211339B1 (pl)
PT (1) PT1411916E (pl)
RU (1) RU2297218C2 (pl)
WO (1) WO2003005954A2 (pl)
ZA (1) ZA200400142B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100851648B1 (ko) 2001-07-09 2008-08-13 레프로스 쎄라피우틱스 아이엔씨. 남성의 테스토스테론 결핍치료용 물질
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
CA2595363C (en) * 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
KR20070114187A (ko) * 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20090105348A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
CA2866905C (en) * 2007-10-16 2016-04-19 Repros Therapeutics, Inc. Selected estrogen receptor modulator (serm) for type 2 diabetes
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) * 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
KR102127348B1 (ko) 2012-05-31 2020-06-29 앨러간 파마슈티컬스 인터내셔널 리미티드 항-프로게스틴의 경질 전달을 위한 제제 및 방법
EP2887922A1 (en) 2012-08-21 2015-07-01 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
EP2914268B1 (en) 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
EP3368506B1 (en) 2016-04-22 2023-09-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
WO1995035093A1 (en) 1994-06-17 1995-12-28 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
RU2089188C1 (ru) * 1994-07-13 1997-09-10 Владимир Александрович Божедомов Способ лечения мужского секреторного бесплодия
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
WO1997006787A2 (en) 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
EP0935523B1 (en) 1996-10-28 2004-09-29 Inc. General Mills Embedding and encapsulation of controlled release particles
HUP0001256A3 (en) 1997-04-03 2002-12-28 Univ Johns Hopkins Med Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, method for making the same and using them
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ES2281186T3 (es) 1998-08-07 2007-09-16 Novartis Vaccines And Diagnostics, Inc. Pirazoles como moduladores de receptores de estrogenos.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CZ299198B6 (cs) 1999-06-11 2008-05-14 Watson Pharmaceuticals, Inc. Souprava a lécivo pro zlepšování zdravotního stavu žen na bázi testosteronu
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CA2409647C (en) 2000-05-26 2012-07-03 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6511986B2 (en) 2000-08-11 2003-01-28 Wyeth Method of treating estrogen receptor positive carcinoma
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
KR100851648B1 (ko) 2001-07-09 2008-08-13 레프로스 쎄라피우틱스 아이엔씨. 남성의 테스토스테론 결핍치료용 물질
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20040235808A1 (en) 2001-09-21 2004-11-25 Jiabing Wang Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
CA2595363C (en) 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
KR20070114187A (ko) 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
KR20080035675A (ko) 2005-08-05 2008-04-23 레프로스 쎄라피우틱스 아이엔씨. 클로미펜을 이용하여 여성의 불임을 치료하는 방법들과조성물들
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
CA2866905C (en) 2007-10-16 2016-04-19 Repros Therapeutics, Inc. Selected estrogen receptor modulator (serm) for type 2 diabetes
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
CA2881604C (en) 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males

Also Published As

Publication number Publication date
PL211339B1 (pl) 2012-05-31
CA2453337C (en) 2012-08-28
CA2777199A1 (en) 2003-01-23
EP1411916A4 (en) 2005-08-17
PT1411916E (pt) 2008-12-10
WO2003005954A3 (en) 2003-10-23
JP2009280623A (ja) 2009-12-03
ECSP044937A (es) 2004-04-28
BR0211067A (pt) 2006-10-31
CO5550428A2 (es) 2005-08-31
US20150265553A1 (en) 2015-09-24
US20140093560A1 (en) 2014-04-03
CN1289075C (zh) 2006-12-13
US7759360B2 (en) 2010-07-20
ES2312593T3 (es) 2009-03-01
KR20040013131A (ko) 2004-02-11
ZA200400142B (en) 2006-02-22
US7368480B2 (en) 2008-05-06
MXPA04000097A (es) 2004-05-21
JP4845165B2 (ja) 2011-12-28
NZ530491A (en) 2007-08-31
US20040097597A1 (en) 2004-05-20
CL2004000026A1 (es) 2005-02-04
CY1108563T1 (el) 2014-04-09
WO2003005954B1 (en) 2003-12-04
CN1551765A (zh) 2004-12-01
CA2453337A1 (en) 2003-01-23
WO2003005954A2 (en) 2003-01-23
KR100851648B1 (ko) 2008-08-13
AU2002318225B2 (en) 2007-12-13
US20100286281A1 (en) 2010-11-11
HK1071521A1 (en) 2005-07-22
CN1954807A (zh) 2007-05-02
US20160354325A1 (en) 2016-12-08
US10561624B2 (en) 2020-02-18
EP1411916B1 (en) 2008-08-27
DK1411916T3 (da) 2008-12-15
US8618176B2 (en) 2013-12-31
NZ551013A (en) 2008-04-30
JP2005520779A (ja) 2005-07-14
RU2004100535A (ru) 2005-06-10
DE60228583D1 (de) 2008-10-09
US20040241224A1 (en) 2004-12-02
EP1411916A2 (en) 2004-04-28
RU2297218C2 (ru) 2007-04-20
ATE406153T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
MXPA04000097A (es) Metodo y materiales para el tratamiento de deficiencias de testosterona en varones.
ZA200309808B (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
TW200501960A (en) Synergistic kits and compositions for treating cancer
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
EP1390014A4 (en) COMPOSITION AND METHODS FOR TREATING HYPERPLASIA
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
IL140917A0 (en) Human anti-factor ix/ixa antibodies
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
IL157457A0 (en) Benzimidazoles that are useful in treating sexual dysfuction
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
CA2408541A1 (en) Treating eczema and/or psoriasis
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
MXPA04005417A (es) Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis.
SI1441761T1 (sl) Postopki za preprečevanje in zdravljenje flavivirusne infekcije pri živalih
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
DE60108359D1 (de) Biologisch wirksame, analoge verbindungen von discodermoliden
AU8200401A (en) Method for treating unstable angina pectoris
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
MXPA03000313A (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea.
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.